Saisei-immune-front
Saisei-clinics-front
Saisei-cancer-front
Saisei-asd-front
Saisei-rejuv-front
previous arrow
next arrow

Saisei Clinics

Saisei Clinics innovates in medicine by using new technologies and collaborations with top research groups globally. We have unique patents aimed at boosting natural immunity and rejuvenating the body at the cellular level. 

Our focus is on enhancing patients’ innate immunity and promoting internal healing, using methods like immunotherapy, rejuvenation therapy and our breakthrough liposomal gene therapy, known for its effectiveness and safety. Clinics aims to assist patients in overcoming various disorders and dysfunctions by normalizing their natural vital immunity, emphasizing a holistic approach to healthcare.

Our concept

Our approaches and products are not solely centered on disease treatment; they also aim to rejuvenate and extend life. We emphasize a comprehensive strategy for normalizing the body, addressing the root causes rather than merely alleviating symptoms. By integrating preventative care with innovative treatment methods, we seek to enhance the body’s resilience against future health challenges. Our focus extends to improving overall well-being. Through this holistic approach, we aim to empower individuals to take charge of their health, ensuring a better quality of life for longer.

Safety of our treatments

At our clinic, each patients are highly valued, and we tailor our approach to provide an individualized combination of treatment methods based on their medical history, predispositions, and current condition. Our guiding principle is “FIRST DO NO HARM.” Our treatments are grounded in scientific research, ensuring safety and minimal side effects. Even if patients are undergoing traditional medical treatments, they can confidently incorporate our methods as complementary therapies.

For more information about our treatment methods, please scroll below.

Saisei Clinics

Saisei Clinics is a pioneering medical clinic that leverages innovative technologies and the latest advancements in medicine through collaborations with leading Japanese and international research institutes and companies. We proudly hold patents for several unique technologies and products designed to enhance natural immunity and rejuvenate the entire body at the cellular level.

While we acknowledge traditional methods of treatment, our primary goal is to assist patients in overcoming various disorders and dysfunctions by harnessing their innate immunity and promoting internal rejuvenation. We focus on normalizing the natural vital immunity of individuals. In addition to immunotherapy, our clinic has developed a cutting-edge form of gene therapy known as liposomal gene therapy, recognized for its exceptional effectiveness and safety.

Macrophage

Our approaches and products are not solely centered on disease treatment; they also aim to rejuvenate and extend life. We emphasize a comprehensive strategy for normalizing the body, addressing the root causes rather than merely alleviating symptoms.

At our clinic, each patients are highly valued, and we tailor our approach to provide an individualized combination of treatment methods based on their medical history, predispositions, and current condition. Our guiding principle is “FIRST DO NO HARM.” Our treatments are grounded in scientific research, ensuring safety and minimal side effects. Even if patients are undergoing traditional medical treatments, they can confidently incorporate our methods as complementary therapies.

For more information about our treatment methods, please scroll below.

Why Choose Us

Innovations

Unique and cutting-edge medical technologies

Empowerment

Our technology is focused on helping your body conquer disease on its own

Global

We have extensive experience treating patients from abroad

Technology

Research-based medical technologies in collaboration with leading institutions

Our Services

We provide support for immunity, cancer, anti-ageing, ASD, brain health etc.

Healthcare
for everyone. 

Immunotherapy

Find out novel immunotherapy methods at Saisei, developed in cooperation with Japanese research institutes.

Rejuvenation

Discover underlying factors of ageing and how you can rejuvenate your body and mind with novel rejuvenation methods at Saisei Clinics.

Autism spectrum disorder (ASD)

What are the main factors of ASD? How is ASD connected with microglia? Learn more about ASD improvement methods at Saisei.

Cancer

Is it possible to defeat cancer? Learn about cutting-edge technologies at Saisei to help your immune system fight cancer.

News

Dr Inui took part in the Integrative Oncology Meet, held in Bangalore, India on November 23, 2023, where he gave a presentation on GcMAF, P53 Gene Therapy and Sono Dynamic Therapy

We successfully concluded the medical conference! A big thank you to all the doctors who presented. 

The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513798/

Conclusion: According to the provided literature overview, we firmly believe that GcMAF deserves be tested as immune-therapeutic to increase macrophages functionality for earlier SARS-CoV-2 viral control, protection against COVID-19 progression by limiting epithelial damage, control local inflammation and prevent from the hyperinflammatory immune response. For this purpose, we planned a Phase-II interventional clinical trial evaluating the effectiveness and safety of Oral immunotherapy with Third Generation GcMAF in hospitalized patients with COVID-19 pneumonia (COral-MAF1 Trial) at the “Ospedale del Mare” Hospital, Naples, Italy.

Saisei Pharma plans clinical study of oral MAF in COVID-19 patients details were featured on some website.
Please check the below URL.

finanzen.ch
advfn.com
chestnutpost.com
benzinga.com

This time, the Saisei Mirai, has contracted official partnership with the Ukrainian National Cancer Center as partner hospitals.

National Cancer Institute of Health Ukraine

Our Team

Dr. Toshio Inui

CEO of Saisei Mirai Clinic group​

Dr. Kentaro Kubo

Director Saisei Mirai Cell Processing Center (CPC)

Dr. Yoko Uchiyama

Medical Doctor Japan

Dr. Akira Takasaki

M.D., PhD
Science Clinic

Dr. Kiyo Fujita

Saisei Serbia

Dr. Galyna Kutsyna

Saisei Ukraine

Joana Bikulciene

Director of Saisei LT

Our Clinics in Japan

We have 3 clinics in Japan: Tokyo, Osaka and Kobe.

Keihan Clinic, Osaka

Saisei Mirai Clinic, Kobe

Science Clinic, Tokyo

Cell Processing Center

Our Clinics Abroad

Saisei Lithuania

Coming soon!
Opening of clinic in Lithuania.
For additional information, please contact us or refer to the Saisei Lithuania website below.
  • Saisei LT, UAB
  • Email: info@saisei.lt
  • Tel: +370 686 66506
  • Web: https://www.saisei.lt/

Saisei Serbia

We are pleased to announce the opening of our clinic in Serbia. For additional information and inquiries, please feel free to contact us using the details below.
  • Tel: +381 11 6707 180
  • Tel: +381 66 803 5888
  • Address: Borisavljevicevay 29, Beograd 11000, Serbia
  • Web: https://saiseiserbia.com/

Saisei Group

Saisei Spain

Saisei Sweden

Saisei Moscow
Temporarily closed

Saisei Ukraine
Temporarily closed

Saisei Pharma is a bio venture company established at Tokushima university in 2014.

We develop, research and manufacture immune activating food products “MAF Series (Capsule, Spray, Candy, Powder)”, ultrasonic sensitizers and electric field therapy (TTF, ECCT) etc.

Our online store offers our Immune activating food products “MAF series” to domestic and overseas customers.

We are now located in Osaka, and our products are produced in a GMP certified factory in Moriguchi, Osaka.

As a Saisei Mira Group, we cooperate with each clinic and will continue our research and development aiming to treat many diseases such as acute infection, chronic infection, cancer, autism, chronic fatigue syndrome, multiple sclerosis, rheumatoid arthritis, Alzheimer’s disease, dementia and so on.

Trusted By

We are collaborating with 6 universities in Japan.

These partnerships allows us to stay at the forefront of medical research and innovation, ensuring that our patients receive the highest quality of care.

Through these affiliations, our clinic remains committed to fostering an environment that encourages continuous learning, professional development, and the implementation of the latest medical breakthroughs. By combining the expertise of our medical professionals with the knowledge generated through these collaborations, we strive to deliver unparalleled healthcare services.

A groundbreaking discovery in Longevity and Rejuvenation!

Saisei has conducted clinical research on the effects of MAF for longevity and rejuvenation. The results were astonishing! Explore further details here.

Recent research and presentation papers

Based on a growing body of evidence that a dysregulated innate immune response mediated by monocytes/macrophages plays a key role in the pathogenesis of COVID-19, a clinical trial was conducted to investigate the therapeutic potential and safety of oral macrophage activating factor (MAF) plus standard of care (SoC) in the treatment of hospitalized patients with COVID-19 pneumonia.

Read more >>

 

MAF Capsules and M Capsules are dietary supplements produced by Saisei Pharma, Japan. They are designated to modulate the mucosal immunity of the intestine. 

Read more >>

The effects of degalactosylated whey protein on lipopolysaccharide (LPS)-induced inflammatory responses in mice were observed in comparison with intact whey protein. 

Read more >>

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)

04-Mar-2021

The clinical trial using MAF capsules has started in Kazakhstan for the patients suffering with coronavirus aftereffects in February 2021.

28-Feb-2021

Update on the clinical trial using MAF for hospitalized COVID-19 patients in Ukraine.
30-Nov-2020
The clinical trial using MAF capsules has started in Italy from November for hospitalised patients with COVID-19.
11-Nov-2020 – Saisei Pharma Announcement
The clinical trial using MAF capsules has started in Ukraine from the end of October for hospitalised patients with COVID-19.
11-Nov-2020 – Saisei Pharma Announcement

Stay young & healthy

GcMAF immunotherapy and longevity treatments at Saisei Mirai Clinics 

Developed by Saisei Mirai and the University of Tokushima in 2010.

High concentration (1500 ng/0.5 ml, 1 dose).

Significantly higher stability and macrophage activating activity.

Sterilization process using 0.22 μm filtration system .

New patented production process 

Subscribe to our YouTube channel

Saisei Movies

Phase 2 Clinical Trial: Evaluating the Efficacy and Safety of MAF Triple for Aging and Longevity

COVID-19: Clinical Trial Results using MAF Triple (Colostrum MAF and Whey MAF) in Ukraine.

Tumor Treating Field (Electric field) therapy: local cancer destruction and immunotherapy.

COVID-19: Clinical Trial, MAF and Integrative Approaches to Treatment

New video on YouTube is available: Saisei Medical conference 2023

Dr. Toshio Inui

“Rejuvenation and a New Challenge in Infectious Diseases Clinical Trials Using Superfood MAF for COVID-19 in Ukraine Clinical Trials for Telomere Extension in Japan..”

Dr. Antonio Jimenez

Founder and Chief Medical officer Hope4Cancer treatment centers
“The connection between the immune system, Aging, and cancer”

Contact Us

    Title *

    Full Name *

    Date of Birth *

    Gender *

    Country *

    Residential Address *

    Telephone number *

    Email Address *


    Email confirmation *

    Clinical Diagnosis *

    Symptoms *



    Get in touch

    Location

    2nd floor, Nature 21 Building
    3-34-8 Okubocho
    Moriguchi, Osaka 570-0012
    Japan

    Contact Us

    Tel : (+81) 06-6902-1001

    Our Hours

    Monday – Friday
    9:00 AM – 5:00 PM

    Coming soon!

    Opening of clinic in Lithuania!
    For additional information, please contact us or refer to the Saisei Lithuania website below.

    We are pleased to announce the opening of our clinic in Serbia. For additional information and inquiries, please feel free to contact us using the details below.

    Tel: +381 11 6707 180
    Tel +381 66 803 5888
    Adress: Sazonova 29, Beograd 11000, Serbia

    You are invited to a Zoom webinar.

    When: Oct 22, 2023 10:00 AM Osaka, Sapporo, Tokyo

    Topic: Saisei Medical Conference 2023 -Advances in Immunotherapy and Rejuvenation: Enhancing Health and Longevity

    Register in advance for this webinar:

    https://us06web.zoom.us/…/reg…/WN_YJIRkF2cSA6iPZb7b4HCwg

    After registering, you will receive a confirmation email containing information about joining the webinar.

    CLINICAL STUDY MAF capsules efficacy in post-COVID syndrome treatment is started in KAZAKHSTAN

    CLINICAL STUDY MAF capsules efficacy in post-COVID syndrome treatment is started in KAZAKHSTAN

    MedInc Ltd in Kazakhstan on the base of National Research Cardiac Surgery Center has started the implementation of prospective randomized open-label clinical trial: “Evaluation of immune modulator MAF capsules efficacy in a therapy of patients with post-COVID syndrome”. The study sponsored by the developer and manufacturer of the study product Saisei Pharma Co. Ltd, Japan.

    The goal of the study is the evaluation of the safety and efficiency of a MAF capsules dietary supplement with anti-inflammatory immune response modulating function in combined treatment of the post-COVID syndrome. |

    The trial started in February 2021 and targeted 200 patients with post-COVID syndrome, which will be randomized 1:1 in two groups:
    Group 1: SOC (standard of care) + dietary supplement MAF capsules administration for 30 days.
    Group 2: SOC

    The study primary endpoints aim to evaluate the improvement within 30 days period after MAF capsules administration, where the clinical efficacy refers to an improvement of life quality according to Chalder Fatigue Scale and the “Postcovid syndrome” consequences and symptoms severity evaluation according to ISARIC questionnaire.

    The study secondary endpoints included the evaluation of changes according to the Karnofsky Performance Scale and Numerical Rating Scale, and evaluation of the MAF capsules side effects.

    The exploratory endpoints include effects on:
    1. Lymphocyte count, T cells and its subpopulation count, and B cells count
    2. The plasma level of IgG against SARS-CoV-2

    6-Jan-2021 Clinical trial using MAF for hospitalized COVID-19 patients in Ukraine In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the investigation of MAF Capsules efficacy as a potential new drug was implemented in the proposed study design. The recommended efficacy endpoints were also implemented in the open-label randomized clinical trial that started in Ukraine in November 2020 to assess the efficacy and safety of dietary supplements MAF Capsules, 148 mg and M Capsules, 148 mg in addition to standard of care (SOC) compared with SOC in the treatment of hospitalized non-critical COVID-19 patients. Summary of preliminary results of clinical study The ongoing interim study results showed a decrease in all-cause mortality and necessity of oxygen supply, as the mortality was 4/15 in the control group, vs 0/16 and 1/17 of currently enrolled patients in the MAF Capsules and M Capsules groups respectively. The mean duration of supplemental oxygen was 8.5 days in the control group, vs 4.1 and 5.1 days in the MAF Capsules and M Capsules groups respectively. MAF Capsules, which is under investigational new drug process, is a dietary supplement that targets guts mucosal immunity to modulate macrophages functionality, limiting epithelial damage, and controlling inflammation response during COVID-19. Clinical trial groups:
    • Control group
    • MAF Capsules (colostrum MAF) group
    • M Capsules (whey MAF) group
    Patients randomized 1:1:1 to:
    1. SOC (standard of care)
    2. SOC plus MAF Capsules (148 mg, 3 caps. TID for 14 days)
    3. SOC plus M Capsules (148 mg, 3 caps. TID for 14 days)
    As compared to the control, both MAF groups showed a clear trend in decreasing mortality
    • No adverse events
    • Decrease in the mortality rate
    • Decrease in necessity and duration of supplemental oxygen
    • Decrease in time to recovery
    • Decrease in time until hospital discharge
    • Preventing of respiratory failure
    • Restoring the base-line decreased lymphocytes count

    3rd Generation GcMAF was developed by Saisei Pharma for which we hold patents. There are fake GcMAF products sold online in Australia by a company which is registered in Hong Kong. Please be aware that 3rd Generation GcMAF products are only produced by Saisei Pharma. Any other products from other companies are fake products.

    30-Nov-2020

    News

    We successfully concluded the medical conference! A big thank you to all the doctors who presented. 

    Keihan Clinic, Kobe Clinic and Science Clinic Cancer treatments, Science Clinic Skin Beauty treatments will be closed from Thursday 29th December 2022 until Tuesday 3th January 2023. We will reopen for business in the new year on Wednesday 4th January 2023.

    The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients.

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513798/

    Conclusion: According to the provided literature overview, we firmly believe that GcMAF deserves be tested as immune-therapeutic to increase macrophages functionality for earlier SARS-CoV-2 viral control, protection against COVID-19 progression by limiting epithelial damage, control local inflammation and prevent from the hyperinflammatory immune response. For this purpose, we planned a Phase-II interventional clinical trial evaluating the effectiveness and safety of Oral immunotherapy with Third Generation GcMAF in hospitalized patients with COVID-19 pneumonia (COral-MAF1 Trial) at the “Ospedale del Mare” Hospital, Naples, Italy.

    Saisei Pharma plans clinical study of oral MAF in COVID-19 patients details were featured on some website.
    Please check the below URL.

    finanzen.ch
    advfn.com
    chestnutpost.com
    benzinga.com

    This time, the Saisei Mirai, has contracted official partnership with the Ukrainian National Cancer Center as partner hospitals.

    National Cancer Institute of Health Ukraine

    Treatment Menu – Cancer / immunotherapy / Skin Rejuvenation
    Cancer Treatment
    Cancer treatment
    Immunotherapy
    Immunotherapy
    Skin rejuvenation
    Skin rejuvenation

    Saisei Pharma

    Collaborative company

    f・clinic - your future clinic -
    error: Content is protected !!